Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal antibody against the @entity10497 , in preventing relapse in @entity1 with @entity11533 ( @entity11533 ). Methods. This retrospective study included clinical data from 40 @entity1 who underwent regular follow-up at our institution in June 2013. Among these @entity1 , 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. Results. The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 @entity1 . Ten @entity1 with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p < 0.01). Among these 10 @entity1 , 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 @entity1 after starting TCZ was significantly higher than that of all 40 @entity1 after the initial treatments (100% and 67% at 12 months, respectively; p = 0.03). Conclusions. TCZ effectively prevented relapses of @entity11533 , and it resolved the disease activity.

The effect of tocilizumab on preventing relapses in XXXX : A retrospective, single-center study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity10497 :: ('3570', 'Gene') :: ['interleukin-6 receptor'] @entity11533 :: ('MESH:D016706', 'Disease') :: ["adult-onset Still's disease", 'AOSD']
@entity11533 :: (MESH:D016706,Disease) :: ['adult-onset Still's disease']
